Current Treatment Approaches in NSCLC With PACC Mutations

Panelists discuss how existing tyrosine kinase inhibitors (TKIs)—first through third generation—demonstrate limited and variable activity against PACC mutations, reflecting the structural challenges these variants pose.

Panelists discuss how real-world treatment strategies often involve empiric use of later-generation TKIs or chemotherapy, with modest response rates compared to those seen in classical EGFR mutations.

Panelists discuss how clinicians must balance efficacy and tolerability while awaiting results from newer agents, emphasizing individualized decisions and the integration of clinical trial opportunities for eligible patients.